Literature DB >> 18590626

[Evaluation and management of hypertension in Spain. A consensus guide].

Alejandro de la Sierra1, Manuel Gorostidi, Rafael Marín, Josep Redón, José R Banegas, Pedro Armario, Juan García Puig, Julio Zarco, José L Llisterri, Carlos Sanchís, Benjamín Abarca, Vicente Palomo, Ramón Gomis, Alfonso Otero, Fernando Villar, Jesús Honorato, Juan Tamargo, José M Lobos, Juan Macías-Núñez, Antonio Sarría, Pedro Aranda, Luis M Ruilope.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18590626     DOI： 10.1157/13124015

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN： 0025-7753            Impact factor:   1.725


× No keyword cloud information.
  10 in total

1.  [Suitability and performance of echocardiogram in primary care].

Authors:  Mariano de la Figuera; Jordi Fernández; María Isabel Fernández; Marta Castelló; Josepa Canadell
Journal:  Aten Primaria       Date:  2011-09-19       Impact factor: 1.137

2.  A cardiovascular educational intervention for primary care professionals in Spain: positive impact in a quasi-experimental study.

Authors:  Vicente Gil-Guillén; Enrique Hermida; Salvador Pita-Fernandez; Antonio Palazon-Bru; Ramon Durazo-Arvizu; Vicente Pallares-Carratala; Domingo Orozco-Beltran; Concepcion Carratala-Munuera; Adriana Lopez-Pineda; Jorge Navarro
Journal:  Br J Gen Pract       Date:  2015-01       Impact factor: 5.386

3.  Hydration status, drug interactions, and determinants in a Spanish elderly population: a pilot study.

Authors:  A M Puga; T Partearroyo; G Varela-Moreiras
Journal:  J Physiol Biochem       Date:  2017-08-10       Impact factor: 4.158

4.  Resistant hypertension: do all definitions describe the same patients?

Authors:  L Boswell; J Pascual; A Oliveras
Journal:  J Hum Hypertens       Date:  2015-01-15       Impact factor: 3.012

5.  [Objective KONTROL study: therapeutic inertia in hypertensive patients attended in primary care of Spain].

Authors:  Carlos Sanchis Doménech; José Luis Llisterri Caro; Vicente Palomo Sanz; Francisco Javier Alonso Moreno; Isidro López Rodríguez; Armando Nevado Loro; Miguel Ángel Zamorano; Natividad Gil García; M Dolores Aguilar Conesa; Pablo Lázaro Y de Mercado
Journal:  Aten Primaria       Date:  2011-03-17       Impact factor: 1.137

6.  Predictors of the community pharmacy white-coat effect in treated hypertensive patients. The MEPAFAR study.

Authors:  Daniel Sabater-Hernández; Pablo Sánchez-Villegas; José P García-Corpas; Pedro Amariles; José Sendra-Lillo; María J Faus
Journal:  Int J Clin Pharm       Date:  2011-04-27

7.  Agreement between community pharmacy and ambulatory and home blood pressure measurement methods to assess the effectiveness of antihypertensive treatment: the MEPAFAR study.

Authors:  Daniel Sabater-Hernández; Alejandro De La Sierra; Pablo Sánchez-Villegas; Fidelina M Santana-Pérez; Luisa Merino-Barber; María J Faus
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-03-05       Impact factor: 3.738

8.  Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care.

Authors:  Carmen de Burgos-Lunar; Miguel A Salinero-Fort; Juan Cárdenas-Valladolid; Sonia Soto-Díaz; Carmen Y Fuentes-Rodríguez; Juan C Abánades-Herranz; Isabel del Cura-González
Journal:  BMC Med Res Methodol       Date:  2011-10-28       Impact factor: 4.615

9.  [Primary care evaluation of the hypertensive patient management in specialized care after derivation (DERIVA-2 Study)].

Authors:  Nieves Martell-Claros; Alberto Galgo Nafría; María Abad-Cardiel; Beatriz Álvarez-Álvarez; José Antonio García Donaire; Emilio Márquez-Contreras; Ángel Molino-González
Journal:  Aten Primaria       Date:  2017-10-14       Impact factor: 1.137

10.  Protocol for assessing the hypotensive effect of evening administration of acetylsalicylic acid: study protocol for a randomized, cross-over controlled trial.

Authors:  Ma Victoria Ruíz-Arzalluz; Ma Cruz Gómez Fernández; Natalia Burgos-Alonso; Ernest Vinyoles; Ricardo San Vicente Blanco; Gonzalo Grandes
Journal:  Trials       Date:  2013-07-27       Impact factor: 2.279
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.